Company: NDRA
Filing Date: 2025-05-09
Form Type: DRS
Source: 0001654954-25-005304
Chunk: 8

Company: ENDRA Life Sciences Inc.
Filing Date: 2025-05-09
Form: DRS
Chunk 8
---
 from this offering to us will be approximately $      million, assuming a public offering price of $      per share, which is the last reported sale price of our common stock on the Nasdaq Capital Market on      , 2025 and after deducting the estimated Underwriter fees and expected offering expenses payable by us.   We intend to use the net proceeds from this offering for research and product development, to fund clinical trials and for working capital and general corporate purposes.   See the section titled “Use of Proceeds.”                                                                                                            |              |
| Nasdaq Capital Market symbol                                              |     | NDRA                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         |              |
| Lock-ups                                                                  |     | [We, our successors and all of our directors, officers and certain holders of more than 5.0% of our outstanding shares of common stock have agreed with the underwriter, subject to certain exceptions, not to sell, transfer or dispose of, directly or indirectly, any of our shares of common stock or securities convertible into or exercisable or exchangeable for our common stock for a period of [90] days after the date of this prospectus, subject to certain exceptions[, including an exception for us to resume sales under our existing at-the-market sales program after the passage of 30 days from the date of this prospectus.] See “Underwriting” for more information. |              |
| Risk factors                                                              |     | See the section titled “Risk Factors” and other information included in this prospectus for a discussion of factors you should consider before investing in our securities.                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                  |              |

_________________

All of the stock numbers in this prospectus take into account both the August Reverse Stock Split and the November Reverse Stock Split.

| 9 |

<div align='center'>CONFIDENTIAL TREATMENT REQUESTED PURSUANT TO 17 C.F.R. § 200.83</div>

| The number of shares of our common stock to be outstanding after this offer is based on 737,270 shares of common stock outstanding as of May 2, 2025 and excludes the following: |                                                                                                                                                                                                                                |
| ·                                                                                                                                                                                | 180,707 shares of common stock issuable upon the exercise of outstanding warrants at a weighted-average exercise price of $85.38 per share;                                                                                    |
| ·                                                                                                                                                                                | 1 share of common stock issuable upon the conversion of outstanding shares of Series A Convertible Preferred Stock;                                                                                                            |
| ·                                                                                                                                                                                | 278 shares of common stock issuable upon the exercise of